Cytokinetics vs Lexicon Pharmaceuticals
CYTK and LXRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CYTK and LXRX compare
Lexicon Pharmaceuticals is the larger company, worth 81 times as much as Cytokinetics ($632M against $7.8M).
Cytokinetics grew revenue faster over the last twelve months (−21.1% versus −29.0% for Lexicon Pharmaceuticals).
Lexicon Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −147% compared with −1321% at Cytokinetics.
Lexicon Pharmaceuticals scores higher on the StockData Score (5 against 4 for Cytokinetics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CYTK | LXRX |
|---|---|---|
| Size and price | ||
| Market cap | $7.8M | $632M |
| Share price | $62.99 | $1.42 |
| Change, 1 year | 1.6% | 6.8% |
| Change, 5 years | 53.3% | −70.7% |
| Beta (5Y) | 0.82 | 1.83 |
| Employees | 673 | 81 |
| StockData Score | ||
| Total score | 4 | 5 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 | 1 |
| Performance score | 1 | 2 (better) |
| Health score | 1 | 2 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.1× (better) | 15.2× |
| P/B | – | 3.6× |
| FCF yield | −7408% | – |
| Fair value | – | $0.964 |
| Margin of safety | – | −47.3% |
| Growth | ||
| Revenue growth (TTM) | −21.1% (better) | −29.0% |
| Revenue growth, 5Y average | 9.5% | 15.7% (better) |
| Profitability | ||
| Gross margin | – | 99.1% |
| Operating margin | −1046% | −131% (better) |
| Net margin | −1321% | −147% (better) |
| FCF margin | −858% | – |
| Return on equity | – | −40.2% |
| Return on invested capital | – | −163% |
| Financial health | ||
| Debt / equity | – | 0.29 |
| Current ratio | 6.66 | 13.37 (better) |
| Altman Z-score | −3.37 (better) | −6.14 |
| Piotroski F-score | 2 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 115% | 81.9% |
| Held by insiders | 0.68% | – |
| Insider net buying, 12 months | −$50.6M | $2.7M (better) |
| Short interest, % of float | 14.0% | – |
Go deeper
- CYTK stock overview
- CYTK income statement
- CYTK valuation and score
- LXRX stock overview
- LXRX income statement
- LXRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.